Search
Plus Therapeutics Inc
PSTVAdd to Watchlist
3.870USD
+0.220+6.03%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.06MMarket Cap
LossP/E TTM
More Details of Plus Therapeutics Inc Company
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Plus Therapeutics Inc Info
Ticker SymbolPSTV
Company namePlus Therapeutics Inc
IPO dateAug 09, 2000
CEOHedrick (Marc H)
Number of employees21
Security typeOrdinary Share
Fiscal year-endAug 09
Address4200 Marathon Blvd.
CityAUSTIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code78756
Phone17372557194
Websitehttp://www.plustherapeutics.com/
Ticker SymbolPSTV
IPO dateAug 09, 2000
CEOHedrick (Marc H)
Company Executives of Plus Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
44.48K
+36.96%
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
5.57K
--
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
1.98K
+46.52%
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Kyle Guse, Esq.
Mr. Kyle Guse, Esq.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
44.48K
+36.96%
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
5.57K
--
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
1.98K
+46.52%
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
FAQs
Who are the top five shareholders of Plus Therapeutics Inc?
The top five shareholders of Plus Therapeutics Inc are: Dr. Marc H. Hedrick, M.D.
How many institutions hold shares of Plus Therapeutics Inc (PSTV)?
As of 2026Q1, 55 institutions hold shares of Plus Therapeutics Inc, with a combined market value of approximately 1.08M, accounting for 15.74% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 825853.00.
What is the biggest source of revenue for Plus Therapeutics Inc?
In 2026Q1, the Consumable business generated the highest revenue for Plus Therapeutics Inc, amounting to 2.17M and accounting for 81.21% of total revenue.